Fig. 1

CBL0137 inhibits B-NHL cell proliferation by inducing cell cycle arrest and promoting apoptosis. A Cell viability of B-NHL cells treated with various concentrations of CBL0137 for 24 h was measured by CCK-8 assay. B B-NHL cells were treated with 0.5 μM, 1.0 μM, 1.5 μM, 2.0 μM CBL0137, and 2.0 μM doxorubicin for 24 h, 48 h, and 72 h. The absorbance values at 450 nm were determined. C Cell proliferation was detected by colony formation assay after 24 h treatment with CBL0137 (1.0 μM). D The cell cycle was determined by flow cytometry. The percentages of cell cycle phases were shown in the bar chart. CBL0137 induced a significant increase in the proportion of B-NHL cells in S phase. E The expression of cyclins, CDKs, c-MYC, p21, and p53 was detected by western blotting in B-NHL cells treated with CBL0137. F Four B-NHL cells (SU-DHL-4, Farage, Raji, and Jeko-1) were treated with specified concentrations of CBL0137 for 24 h. Cell apoptosis was assessed by the Annexin V-FITC Apoptosis Detection Kit and flow cytometry. Representative results are shown on the left and statistical results are shown on the right. G B-NHL cells were treated with different concentrations of CBL0137 for 24 h and then were collected, and chromosomal DNA was isolated and purified using DNA Ladder Detection Kit according to manufacturer's instructions to explore the effect of CBL0137 on DNA fragmentation in B-NHL cells. H, I Representative proteins expression in four B-NHL cells treated with different concentrations of CBL0137 and vehicle control (DMSO) for 24 h to evaluate the status of apoptotic cascade and mitochondrial apoptosis. The data are representative and taken from one of three independent experiments. The data results are expressed as mean ± SD (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, Student’s t-test)